Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
post
Last Updated on: 24 November, 2024
Author: Getaka|Social: Getaka Financial Services X (Earlier Twitter) Profile Getaka Financial Services LinkedIn Logo
Stock Ticker - BSE: 524742 | NSE: CAPLIPOINT

Caplin Point Laboratories Ltd: Intrinsic Value and Fundamental Analysis

Share Price and Basic Stock Data

Last Updated: November 22, 2024, 11:27 pm

Market Cap 14,921 Cr.
Current Price 1,964
High / Low2,177/1,178
Stock P/E30.2
Book Value 334
Dividend Yield0.25 %
ROCE26.5 %
ROE24.2 %
Face Value 2.00
PEG Ratio2.09

Stock P/E, Current Price, and Intrinsic Value Over Time

View Share Price Target for Caplin Point Laboratories Ltd

Competitors of Caplin Point Laboratories Ltd

Stock NameMarket CapCurrent PriceHigh / LowStock P/EBook ValueDividend YieldROCEROEFace Value
Gujarat Themis Biosyn Ltd 3,399 Cr. 312390/10864.5 20.50.21 %45.0 %33.8 % 1.00
Gujarat Terce Laboratories Ltd 58.6 Cr. 79.094.9/25.822.5 11.90.00 %9.72 %3.44 % 10.0
Gujarat Inject (Kerala) Ltd 28.0 Cr. 19.119.5/8.3536.3 6.640.00 %4.06 %3.33 % 10.0
Godavari Drugs Ltd 86.2 Cr. 114155/87.012.9 55.40.00 %12.7 %15.5 % 10.0
Glenmark Life Sciences Ltd 12,800 Cr. 1,0461,335/62030.2 2072.15 %28.1 %21.1 % 2.00
Industry Average19,451.65 Cr1,190.0155.13184.880.32%16.40%16.92%6.61

All Competitor Stocks of Caplin Point Laboratories Ltd

Quarterly Result

MonthJun 2021Sep 2021Dec 2021Mar 2022Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024
Sales300304326339346359372389395410436453459
Expenses208202225239244253263265269273293308307
Operating Profit93101101100102106109124127137142145152
OPM %31%33%31%29%30%29%29%32%32%34%33%32%33%
Other Income981012141614111221171719
Interest0000000000000
Depreciation12121211111111111112141616
Profit before tax909899100105110112124127146145146154
Tax %20%21%20%19%18%17%13%18%18%20%18%17%19%
Net Profit72777981869297101104116120121125
EPS in Rs9.379.919.8910.4311.2112.0912.8413.4513.6215.1315.4316.0116.31

Last Updated: September 12, 2024, 5:12 pm

Quarterly Chart

Profit & Loss - Annual Report

Last Updated: September 12, 2024, 5:12 pm

MonthJun 2013Jun 2014Jun 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024TTM
Sales1271732522394025406498631,0611,2691,4671,6941,758
Expenses1051371921752763454176037328741,0251,1421,181
Operating Profit22366064125195232260329395442552577
OPM %18%21%24%27%31%36%36%30%31%31%30%33%33%
Other Income2434101319412338556674
Interest1110111021111
Depreciation2487131923323747455358
Profit before tax22365360121188227269314386451564592
Tax %37%27%23%24%21%23%22%20%20%20%16%18%
Net Profit1426414696145177215251308377461482
EPS in Rs1.853.425.436.0512.6519.1523.3528.4232.0339.5649.5760.1962.88
Dividend Payout %27%23%18%20%12%10%9%9%9%10%9%8%

Profit & Loss Yearly Chart

YoY Net Profit Growth

Year2016-20172017-20182018-20192019-20202020-20212021-20222022-20232023-2024
YoY Net Profit Growth (%)108.70%51.04%22.07%21.47%16.74%22.71%22.40%22.28%
Change in YoY Net Profit Growth (%)0.00%-57.65%-28.97%-0.60%-4.72%5.96%-0.31%-0.12%

Caplin Point Laboratories Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 8 years from 2016-2017 to 2023-2024.

Growth

Compounded Sales Growth
10 Years:30%
5 Years:21%
3 Years:17%
TTM:17%
Compounded Profit Growth
10 Years:42%
5 Years:21%
3 Years:24%
TTM:18%
Stock Price CAGR
10 Years:37%
5 Years:43%
3 Years:37%
1 Year:60%
Return on Equity
10 Years:29%
5 Years:26%
3 Years:25%
Last Year:24%

Last Updated: Unknown

Balance Sheet

Last Updated: November 15, 2024, 1:33 am

MonthJun 2013Jun 2014Jun 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Sep 2024
Equity Capital15151515151515151515151515
Reserves2847781132103495828589541,2521,6492,0842,527
Borrowings532211361132352192222192
Other Liabilities87115134137133136109139159250305380379
Total Liabilities1351802292673585007431,1261,3641,7362,1912,6982,924
Fixed Assets33102113144152169227272305287280453465
CWIP512531031510201418221117153
Investments1000174770611189281376514
Other Assets5052851221862694367721,0331,3431,4101,7531,792
Total Assets1351802292673585007431,1261,3641,7362,1912,6982,924

Reserves and Borrowings Chart

Cash Flow

MonthJun 2013Jun 2014Jun 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024
Cash from Operating Activity +3260504268668345269337271318
Cash from Investing Activity +-45-44-23-6-36-69-100-54-30-377-216-319
Cash from Financing Activity +-1-6-9-14-7-129080-24-41-28-38
Net Cash Flow-1510192325-147370215-8127-39

Free Cash Flow

MonthJun 2013Jun 2014Jun 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024
Free Cash Flow17.0033.0058.0062.00124.00194.00196.00147.0094.00176.00220.00333.00

Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)

Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.

Free Cash Flow Chart

Financial Efficiency Indicators

MonthJun 2013Jun 2014Jun 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024
Debtor Days2081230859097969198117
Inventory Days45353757444447210139149159183
Days Payable11111211216815514476576810284106
Cash Conversion Cycle-63-77-67-99-81-1661251166138173194
Working Capital Days-176-181-128-114-2947104167152166146166
ROCE %52%64%68%62%68%63%45%33%28%28%26%26%

Financial Efficiency Indicators Chart

Share Holding Pattern

MonthSep 2021Dec 2021Mar 2022Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024
Promoters69.03%68.91%68.89%68.88%68.88%68.80%70.66%70.63%70.62%70.62%70.62%70.56%
FIIs1.76%2.11%2.07%2.03%2.15%2.24%2.36%2.68%3.09%2.84%3.33%3.38%
DIIs1.19%1.22%1.25%1.12%1.12%1.12%0.64%0.27%0.21%0.43%1.08%1.49%
Public28.02%27.76%27.78%27.97%27.85%27.84%26.33%26.44%26.08%26.11%24.95%24.59%
No. of Shareholders83,46285,57783,82984,86884,53882,68782,14678,95678,06879,43881,40980,411

Shareholding Pattern Chart

No. of Shareholders

Mutual Fund Holdings

Fund NameNo of SharesAUM (%)Amount Invested (Cr)Previous Number of SharesPrevious DatePercentage Change
UTI Aggressive Hybrid Fund243,1640.6338.28243,1642024-11-230%
UTI Large & Mid Cap Fund154,0970.6524.26243,1642024-11-23-36.63%
UTI Healthcare Fund120,0001.7418.89243,1642024-11-23-50.65%
UTI Retirement Fund107,3270.3616.89243,1642024-11-23-55.86%
ITI Pharma and Healthcare Fund14,7581.272.32243,1642024-11-23-93.93%
Navi Aggressive Hybrid Fund3,6000.510.57243,1642024-11-23-98.52%

ROCE Trend

EPS Trend

Key Financial Ratios

MonthMar 24Mar 23Mar 22Mar 21Mar 20
FaceValue2.002.002.002.002.00
Basic EPS (Rs.)60.1949.6239.6132.0328.42
Diluted EPS (Rs.)59.9049.1839.2631.7128.20
Cash EPS (Rs.)67.7555.6046.8838.1332.61
Book Value[Excl.RevalReserv]/Share (Rs.)309.00241.46189.35159.08116.60
Book Value[Incl.RevalReserv]/Share (Rs.)309.00241.46189.35159.08116.60
Revenue From Operations / Share (Rs.)223.05193.25167.47140.30114.12
PBDIT / Share (Rs.)81.4265.4957.1846.5639.85
PBIT / Share (Rs.)74.3859.5650.9941.6735.66
PBT / Share (Rs.)74.2859.4750.9041.4635.62
Net Profit / Share (Rs.)60.7249.6740.6933.2428.43
NP After MI And SOA / Share (Rs.)60.1849.5739.5632.0328.42
PBDIT Margin (%)36.5033.8834.1433.1834.91
PBIT Margin (%)33.3430.8230.4429.7031.25
PBT Margin (%)33.3030.7730.3929.5531.21
Net Profit Margin (%)27.2225.7024.2923.6924.91
NP After MI And SOA Margin (%)26.9825.6523.6222.8224.90
Return on Networth / Equity (%)19.7320.8321.2720.4324.61
Return on Capital Employeed (%)23.8623.5025.2825.8227.48
Return On Assets (%)16.9417.1617.2617.7619.09
Total Debt / Equity (X)0.000.000.000.010.04
Asset Turnover Ratio (%)0.690.740.430.480.73
Current Ratio (X)5.725.806.257.255.70
Quick Ratio (X)4.634.725.156.004.05
Inventory Turnover Ratio (X)0.730.801.410.853.20
Dividend Payout Ratio (NP) (%)0.008.050.001.240.00
Dividend Payout Ratio (CP) (%)0.007.190.001.080.00
Earning Retention Ratio (%)0.0091.950.0098.760.00
Cash Earning Retention Ratio (%)0.0092.810.0098.920.00
Interest Coverage Ratio (X)792.79637.23619.17221.55942.76
Interest Coverage Ratio (Post Tax) (X)592.22484.22441.64159.17673.77
Enterprise Value (Cr.)9484.474065.674717.102632.141957.49
EV / Net Operating Revenue (X)5.602.773.722.482.27
EV / EBITDA (X)15.348.1810.887.476.49
MarketCap / Net Operating Revenue (X)5.913.094.062.882.47
Retention Ratios (%)0.0091.940.0098.750.00
Price / BV (X)4.322.513.662.582.45
Price / Net Operating Revenue (X)5.913.094.062.882.47
EarningsYield0.040.080.050.070.10

Profitability Ratios (%)

Liquidity Ratios

Liquidity Ratios (%)

Interest Coverage Ratios (%)

Valuation Ratios

Fair Value

Fair Value of Caplin Point Laboratories Ltd as of November 24, 2024 is: 2,447.11

Calculation basis:

  • Fair value = P/E Ratio * (Return on Equity / 100) * Book Value * (1 + Dividend Yield / 100)
  • P/E Ratio (Price-to-Earnings Ratio): Represents the price of the stock relative to its earnings per share. A higher P/E ratio indicates that investors are willing to pay a higher price for the stock.
  • Return on Equity (ROE): Measures a company's profitability relative to its shareholder equity. It showcases the company's ability to generate profits using the investment made by its shareholders, offering valuable insight into its operational efficiency and financial performance.
  • Book Value: Represents the net asset value of the company per share. It is calculated as the total assets minus intangible assets and liabilities, divided by the number of outstanding shares.
  • Dividend Yield: The ratio of the annual dividend per share to the current market price per share. It offers valuable insights into the profitability of an investment through dividends.

This formula allows us to gauge the fair value of the stock by analyzing its fundamental indicators.

As of November 24, 2024, Caplin Point Laboratories Ltd is Undervalued by 24.60% compared to the current share price 1,964.00

Intrinsic Value of Caplin Point Laboratories Ltd as of November 24, 2024 is: 2,800.56

Calculation basis:

  • Intrinsic value = P/E Ratio * (Return on Equity / 100) * Book Value * (1 + Dividend Yield / 100) * (1 + EPS CAGR for Last 5 Years)
  • P/E Ratio (Price-to-Earnings Ratio): Represents the price of the stock relative to its earnings per share. A higher P/E ratio indicates that investors are willing to pay a higher price for the stock.
  • Return on Equity (ROE): Measures a company's profitability relative to its shareholder equity. It showcases the company's ability to generate profits using the investment made by its shareholders, offering valuable insight into its operational efficiency and financial performance.
  • Book Value: Represents the net asset value of the company per share. It is calculated as the total assets minus intangible assets and liabilities, divided by the number of outstanding shares.
  • Dividend Yield: The ratio of the annual dividend per share to the current market price per share. It offers valuable insights into the profitability of an investment through dividends.
  • EPS CAGR (Compound Annual Growth Rate): Represents the geometric mean growth rate of earnings per share over the last 5 years. It provides insight into the historical growth trajectory of the company's earnings.

This formula allows us to gauge the intrinsic value of the stock by analyzing its fundamental indicators along with EPS growth.

As of November 24, 2024, Caplin Point Laboratories Ltd is Undervalued by 42.59% compared to the current share price 1,964.00

Last 5 Year EPS CAGR: 14.44%

*Investments are subject to market risks

Strength and Weakness

StrengthWeakness
  1. The stock has a high average ROCE of 46.92%, which is a positive sign.
  2. The stock has a low average Working Capital Days of 26.67, which is a positive sign.
  3. The company has higher reserves (825.46 cr) compared to borrowings (81.54 cr), indicating strong financial stability.
  4. The company has shown consistent growth in sales (250.00 cr) and profit (252.54 cr) over the years.
  1. The stock has a high average Cash Conversion Cycle of 48.33, which may not be favorable.

Stock Analysis

  • Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Caplin Point Laboratories Ltd:
    1. Net Profit Margin: 27.22%
      • Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
    2. ROCE: 23.86% (Industry Average ROCE: 16.4%)
      • ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
    3. ROE%: 19.73% (Industry Average ROE: 16.92%)
      • ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
    4. Interest Coverage Ratio (Post Tax): 592.22
      • Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
    5. Quick Ratio: 4.63
      • Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
    6. Stock P/E: 30.2 (Industry average Stock P/E: 55.13)
      • Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
    7. Total Debt / Equity: 0
      • Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
    The current analysis is available for review. It's important to conduct thorough research and consider consulting with financial professionals before making any investment decisions.
    Stock Rating:

About the Company - Qualitative Analysis

Caplin Point Laboratories Ltd. is a Public Limited Listed company incorporated on 16/04/1990 and has its registered office in the State of Tamil Nadu, India. Company’s Corporate Identification Number(CIN) is L24231TN1990PLC019053 and registration number is 019053. Currently Company is involved in the business activities of Manufacture of pharmaceuticals, medicinal chemical and botanical products. Company’s Total Operating Revenue is Rs. 528.06 Cr. and Equity Capital is Rs. 15.16 Cr. for the Year ended 31/03/2022.
INDUSTRYADDRESSCONTACT
Pharmaceuticals3rd Floor, Ashvich Towers, No.3, Developed Plots Industrial Chennai (Madras) Tamil Nadu 600096info@caplinpoint.net
www.caplinpoint.net
Management
NamePosition Held
Mr. C C PaarthipanChairman
Dr. Sridhar GanesanManaging Director
Dr. R NagendranIndependent Director
Mr. S DeenadayalanIndependent Director
Mr. D SathyanarayananIndependent Director
Dr. C K GariyaliIndependent Director

FAQ

What is the latest intrinsic value of Caplin Point Laboratories Ltd?

The latest intrinsic value of Caplin Point Laboratories Ltd as on 24 November 2024 is ₹2447.11, which is 24.60% higher than the current market price of ₹1,964.00.

What is the Market Cap of Caplin Point Laboratories Ltd?

The Market Cap of Caplin Point Laboratories Ltd is 14,921 Cr..

What is the current Stock Price of Caplin Point Laboratories Ltd as on 24 November 2024?

The current stock price of Caplin Point Laboratories Ltd as on 24 November 2024 is 1,964.

What is the High / Low of Caplin Point Laboratories Ltd stocks in FY 2024?

In FY 2024, the High / Low of Caplin Point Laboratories Ltd stocks is 2,177/1,178.

What is the Stock P/E of Caplin Point Laboratories Ltd?

The Stock P/E of Caplin Point Laboratories Ltd is 30.2.

What is the Book Value of Caplin Point Laboratories Ltd?

The Book Value of Caplin Point Laboratories Ltd is 334.

What is the Dividend Yield of Caplin Point Laboratories Ltd?

The Dividend Yield of Caplin Point Laboratories Ltd is 0.25 %.

What is the ROCE of Caplin Point Laboratories Ltd?

The ROCE of Caplin Point Laboratories Ltd is 26.5 %.

What is the ROE of Caplin Point Laboratories Ltd?

The ROE of Caplin Point Laboratories Ltd is 24.2 %.

What is the Face Value of Caplin Point Laboratories Ltd?

The Face Value of Caplin Point Laboratories Ltd is 2.00.

About the Author

Author Avatar
Getaka

Getaka, CFA, a financial analyst with 15 years of experience in the industry. Getaka holds an MBA degree and the Chartered Financial Analyst designation, demonstrating his profound understanding of financial analysis and investment management. Throughout his career, he has conducted numerous financial analyses and due diligence processes for companies in the industry, and has a strong track record of identifying key trends and opportunities. He leverages his expertise to deliver a thorough financial analysis of a company, encompassing its financial performance, key ratios, future prospects, and risks. Getaka is committed to providing accurate, reliable, and trustworthy information to help readers make informed decisions about their finances and investments.

Disclaimer: This article is for informational purposes only and should not be construed as financial advice. The author is not a SEBI registered financial advisor and does not have any vested interest in Caplin Point Laboratories Ltd. Investors are advised to conduct their own due diligence and consult with a financial professional before making any investment decisions. The information provided in this article is based on publicly available data and the author's analysis, but it may not be comprehensive or up-to-date. The author and getaka.co.in are not responsible for any errors or omissions in the content. This article is not intended to promote any particular investment strategy or recommendation, and readers should consult with their own financial advisors before making any investment decisions. Data Source: NSE